"The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfiel"...
Omontys Side Effects Center
Medical Editor: Charles Patrick Davis, MD, PhD
Omontys (peginesatide) is a once-a-month injectable medication that is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Side effects of Omontys can include diarrhea, nausea, vomiting, back pain, cough, and muscle spasms.
As an initial treatment, Omontys should be dosed once monthly as 0.04 mg/kg body weight. Omontys is a new erythropoiesis-stimulating agent (ESA) that aids in the formation of red blood cells. It works by stimulating the bone marrow to produce more red blood cells, usually measured as hemoglobin levels, to reduce the need for transfusions in patients with CKD.
There are no adequate and well-controlled studies in pregnant women. Omontys should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether peginesatide is excreted in human milk. Because many drugs are excreted into human milk, caution should be exercised when Omontys is administered to a nursing woman.
Our Omontys Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Omontys in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Contact your doctor if you feel weak, lightheaded, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to this medication.
Peginesatide can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use peginesatide. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:
- chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
- sudden numbness or weakness, especially on one side of the body;
- sudden severe headache, confusion, problems with vision, speech, or balance;
- chest pain, sudden cough, wheezing, rapid breathing, coughing up blood;
- pain, swelling, warmth, or redness in one or both legs;
- numbness, tingling, cold feeling, or pale appearance in your arms or legs;
- feeling short of breath, even with mild exertion;
- swelling, rapid weight gain;
- feeling light-headed, fainting; or
- if your hemodialysis vein access stops working.
Call your doctor at once if you have any other serious side effect such as:
- easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
- feeling light-headed, fainting;
- pale skin, feeling short of breath, rapid heart rate, trouble concentrating;
- high potassium (slow heart rate, weak pulse, muscle weakness, tingly feeling);
- seizure (convulsions); or
- dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).
Less serious side effects may include:
- nausea, vomiting, diarrhea;
- back pain, muscle spasm, pain in your arms or legs;
- joint pain; or
- cold symptoms such as stuffy nose, sneezing, sore throat.
Read the entire detailed patient monograph for Omontys (Peginesatide) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Omontys FDA Prescribing Information: Side Effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
- Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism [see WARNINGS AND PRECAUTIONS]
- Hypertension [see WARNINGS AND PRECAUTIONS]
- Serious allergic reactions [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of OMONTYS cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.
Patients with Chronic Kidney Disease
Adverse reactions were determined based on pooled data from two active controlled studies of 1066 dialysis patients treated with OMONTYS and 542 treated with epoetin, including 938 exposed for at least 6 months and 825 exposed for greater than one year to OMONTYS. The population for OMONTYS was 20 to 93 years of age, 58.5% male, and the percentages of Caucasian, Black (including African Americans), and Asian patients were 57.9%, 37.4%, and 3.1%, respectively. The median weight adjusted dose of OMONTYS was 0.07 mg/kg and 113 U/week/kg of epoetin.
Table 3 summarizes the most frequent adverse reactions ( ≥ 10%) in dialysis patients treated with OMONTYS.
Table 3 : Adverse Reactions Occurring in ≥ 10%
of Dialysis Patients treated with OMONTYS
|Adverse Reactions||Dialysis Patients Treated with OMONTYS
(N = 1066)
|Dialysis Patients Treated with Epoetin
(N = 542)
|Respiratory, Thoracic and Mediastinal Disorders|
|Injury, Poisoning and Procedural Complications|
|Arteriovenous Fistula Site Complication||16.1%||16.6%|
|Nervous System Disorders|
|Musculoskeletal and Connective Tissue Disorders|
|Pain in Extremity||10.9%||12.7%|
|General Disorders and Administration Site Conditions|
|Metabolism and Nutrition Disorders|
|Infections and Infestations|
|Upper Respiratory Tract Infection||11.00%||12.40%|
Seizures have occurred in patients participating in OMONTYS clinical studies. During the first several months following initiation of OMONTYS, blood pressure and the presence of premonitory neurologic symptoms should be monitored closely.
Advise patients to contact their healthcare practitioner for new-onset seizures, premonitory symptoms, or change in seizure frequency.
Allergic and infusion-related reactions have been reported in patients treated with OMONTYS.
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Serious allergic reactions have been reported during postmarketing use of OMONTYS [see WARNINGS AND PRECAUTIONS].
Of the 2357 patients tested during clinical trials, 29 (1.2%) had detectable levels of peginesatide-specific binding antibodies. There was a higher incidence of peginesatide-specific binding antibodies in patients dosed subcutaneously (1.9%) as compared to those dosed intravenously (0.7%). Peginesatide neutralizing antibodies were detected in vitro using a cell-based functional assay in 21 of these patients (0.9%). In approximately half of all antibody-positive patients, the presence of antibodies was associated with declining hemoglobin levels, the requirement for increased doses of OMONTYS to maintain hemoglobin levels, and/or transfusion for anemia of CKD. No cases of pure red cell aplasia (PRCA) developed in patients receiving OMONTYS during clinical trials.
Read the entire FDA prescribing information for Omontys (Peginesatide) »
Additional Omontys Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.